Sarah B Gitto, PhD
Research Assistant Professor of Radiology
Associate Member, Institute for Translational Medicine and Therapeutics
Associate Member, Abramson Cancer Center
Member, Center for Women's Health and Reproductive Medicine
Member, Ovarian Cancer Research Center
Member, Center for Cellular Immunotherapies
Department: Radiology
Contact information
3620 Hamilton Walk
John Morgan Building, Room 168C
Philadelphia, PA 19104
John Morgan Building, Room 168C
Philadelphia, PA 19104
Publications
Education
B.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
B.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Permanent linkB.S. (Health Sciences, Pre-Clinical Track )
University of Central Florida, 2011.
B.S. (Molecular Biology and Microbiology)
University of Central Florida, 2011.
M.S. (Biomedical Sciences)
University of Central Florida, 2014.
Ph.D. (Biomedical Sciences)
University of Central Florida, 2017.
M.S. (Translational Science)
University of Pennsylvania, 2022.
Selected Publications
Gitto SB, Hughes S, Paul M, Bom S, Burchett R, Morreale BG, Pannucci A, Rono C, Weigel C, Wolf CL, Williams JE Jr, Cohn W, Gibson H, Dolatshahi S, Gupta A, Rutkowshi MR, Anderson KG: Opportunities to enhance cancer research through advocate-researcher partnerships. Cancer Research June 2026.Koopman LA, Alemdehy F, dr Poot SAH, Paauwe M, Wang W, Epstein K, van den Brink E, Gorlani A, Verzijl D, Brandhorst M, Franken P, Vries LS, Gielen E, Plantinga TS, Houtkamp M, Engelberts PJ, Egerog FL, Thalhauser CJ, Bosgra S, Gitto SB, Powell DJ Jr, Gamse JT, Overdijk MB, Breiji ECW: Preclinical comparison of two CD3xB7H4 bispecific antibodies for solid tumor therapy reveals CD3 affinity-dependent potency and tolerability tradeoffs. Molecular Cancer Therapeutics June 2026 Notes: Provisionally Accepted.
Gitto SB, Riad A, McArthur A, Babazada H, Nakkina S, Simpkins F, Mankoff DA, Mach RH, Farwell MD: PARP-targeted theranostic approach to image and treat ovarain cancer. Journal of Nuclear Medicine 67: 262154-262154, May 2026.
Onecha VV, Gitto SB, Riad A, Farwell MD, Pryma DA, Bertolet A: A monte carlo dosimetry-based cell survival model incorporating spatial and temporal heterogeneity for RPT preclinical studies: TU-730-209-2. Medical Physics 52: e70059479, October 2025.
Kinose Y, Xu H, Kim H, Wang X, Kumar S, Shan X, George E, Medvedev S, Ortiz A, Gitto SB. Whicker M, D’Andrea K, Wubbenhost B, Hallberg D, O’Connor M, Schwartz L, Hwang W, Nathanson KL, Mills G, Velculescu VE, Wang T, Brown E, Drapkin R, Simpkins F: Target clear cell ovarian cancers with ARID1A loss by combination inhibition of BRD4 and ATR. Molecular Cancer Therapeutics October 2025.
Riad A, McAuthur A, Babazada H, Mankoff D, Mach RH, Farwell FD, Gitto SB: Preclinical evaluation of PTT, an At-211-labeled rucaparib analogue, as a therapeutic agent for cancer therapy. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.
Gitto SB, Riad A, McArthur A, Simpkins F, Pryma DA, Farwell MD: PARP-targeted alpha therapy for the treatment of PARP-inhibitor resistant ovarian cancer. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.
Nakkina SP, Medvedev S, Ma K, Anderson M, Simpkins F, Powell DJ Jr., Gitto SB: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer. Proceedings of the AACR Special Conference in Cancer Research: Advances in Ovarian Cancer Research September 2025.
Young A, Bagheri S, Kiani M, Gitto S, Sharaf O, Wu G, Lee J, Clark A, Zuckerman S, Lee H, Pantel A, Schubert E, Mankoff D, Mach R, McDonald E: Early reductions in [18F]FlourThanatrace uptake after PARP inhibitor therapy are prior to expected cell death. Journal of Nuclear Medicine June 2025.
Onecha VV, Suarez-Garcia D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A.: Space- and time-defined Monte Carlo dosimetry explains ovarian cancer cell viability in targeted a-particle therapy with astatine 211-ParaThanatrace. International Journal of Radiation Oncology, Biology, and Physics June 2025.
